Journal article
Treatment-free Survival After First-line Therapies for Metastatic Renal Cell Carcinoma: An International Metastatic Renal Cell Carcinoma Database Consortium Analysis
Abstract
BACKGROUND AND OBJECTIVE: Patients receiving immune checkpoint blockade (ICB) therapy may experience periods of prolonged disease control without a need for systemic therapy. Treatment-free survival (TFS) is an important measure for this period, but no data are available for patients with metastatic renal cell carcinoma (mRCC) starting first-line agents. Our aim was to analyze TFS outcomes for patients with mRCC starting first-line therapy.
Authors
Gupta M; Wells C; Regan MM; Xie W; Navani V; Saliby RM; Basappa NS; Donskov F; Yuasa T; Takemura K
Journal
European Urology Oncology, Vol. 8, No. 1, pp. 171–178
Publisher
Elsevier
Publication Date
February 2025
DOI
10.1016/j.euo.2024.12.011
ISSN
2588-9311